Xenitra™

The Formula*asia*™ Ecosystem

xenitra.com

ASX Anouncement **7 May 2026**

For personal use only

$1.25m Raised to Support Next Phase of Growth

Xenitra Limited (ASX:XEN) (the **Company**) is pleased to announce that it has received commitments from institutional, professional and sophisticated investors to raise $1.25m (**Placement**).

Under the Placement, the Company will issue up to 416,666,667 fully paid ordinary shares (**Shares**) at an issue price of $0.003 per Share. The Placement includes one (1) attaching unquoted option (**Option**) for each two (2) Placement Shares. The Options will be exercisable at $0.004 each expiring on 2 April 2028 and be issued subject to shareholder approval.

The funds raised will be deployed for:

- the acceleration of the OTC medicines expansion;
- scaling of the OPAL RWA token ecosystem across new brands;
- working capital and infrastructure for growth; and
- costs of the Placement.

The Placement Shares will be issued utilising the Company's existing Listing Rule 7.1 capacity.

Novus Capital Limited (**Novus**) acted as sole lead manager to the Placement and is entitled to a management and selling fee of 6% of the Placement amount. 30,000,000 Options and 15,000,000 Shares will be issued to Novus, or their nominees, subject to shareholder approval.

Authorised by the board of Xenitra Limited.

For further information please contact:

Sebastian Andre
Comany Secretary
www.xenitra.com